Scandinavian ChemoTech Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Stefan Frick

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	11.8yrs
Eigendom CEO	5.8%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

CEO

Stefan Frick (50 yo)

11.8yrs

Tenure

Mr. Stefan Mohan Frick founded Scandinavian ChemoTech AB in 2013 and has been its Chief Executive Officer since 2015. Mr. Frick has experience in life science marketing and sales from OnMeD, ArjoHuntleigh,...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Stefan Frick	Founder	9.8yrs	geen gegevens	5.81% € 203.8k
Robin Sukhia	Independent Chairman	4.8yrs	geen gegevens	geen gegevens
Rolf Ehrnstrom	Independent Director	4.8yrs	geen gegevens	geen gegevens
Bengt Georg Engstrom	Independent Director	4.8yrs	geen gegevens	0.38% € 13.4k
Nicolas Pepin	Independent Director	1.8yrs	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 8V6 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Scandinavian ChemoTech Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Scandinavian Chemotech Thanks for the Cooperation with Its IR Consultant Who Leaves the Management Team

Robin Sukhia Elects as the New Chairman of the Board for Scandinavian ChemoTech AB (publ)

High number of new and inexperienced directors

Scandinavian Chemotech Appoints Dr. Mufti as Medical Director

Scandinavian ChemoTech AB (publ) Announces Management Changes

High number of new and inexperienced directors

Recent updates

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released

Scandinavian ChemoTech AB (publ) Announces Clinical Update

Second quarter 2024 earnings released

New major risk - Shareholder dilution

Scandinavian Chemotech Announces Clinical Trial Progress

First quarter 2024 earnings released

New major risk - Revenue and earnings growth

Scandinavian Chemotech AB (Publ) Obtains Approval of the Third and Last Patent Application in India

Scandinavian ChemoTech AB (publ) Attains Progress by Obtaining Patent Protection for Two Essential Patents in India

Full year 2023 earnings released: kr1.52 loss per share (vs kr2.28 loss in FY 2022)

Scandinavian ChemoTech AB (publ) to Report Fiscal Year 2024 Results on Mar 04, 2025

Scandinavian ChemoTech AB (publ) to Report Q4, 2024 Results on Mar 04, 2025

Scandinavian Chemotech Thanks for the Cooperation with Its IR Consultant Who Leaves the Management Team

Third quarter 2023 earnings released

Scandinavian ChemoTech AB (publ) to Report Nine Months, 2023 Results on Oct 17, 2023

Second quarter 2023 earnings released

Robin Sukhia Elects as the New Chairman of the Board for Scandinavian ChemoTech AB (publ)

First quarter 2023 earnings released

Full year 2022 earnings released: kr2.36 loss per share (vs kr2.05 loss in FY 2021)

Scandinavian ChemoTech's Fully Owned Subsidiary Vetiqure Receives Very Promising Updates from the Veterinarians At the Royal Veterinary College

Scandinavian ChemoTech AB (publ) to Report Q1, 2023 Results on May 25, 2023

Third quarter 2022 earnings released

Scandinavian Chemotech Receives Updates For Cancer Patients Treated with IQwaveTM Tumour Specific Electroporation™ (Tse) At Ulis Hospital Ukraine

High number of new and inexperienced directors

Scandinavian Chemotech Appoints Dr. Mufti as Medical Director

Scandinavian ChemoTech AB (publ) to Report Q3, 2022 Results on Nov 22, 2022

Scandinavian ChemoTech AB (publ) Announces Management Changes

Second quarter 2022 earnings released

Scandinavian ChemoTech Announces TSE™ Therapy Has Been Initiated At Ulis Medical Centre in Ukraine

Scandinavian ChemoTech Receives Ethics Committee Approval for A Clinical Trial with the TSE Technology At All India Institute of Medical Sciences (AIIMS) in India

Scandinavian ChemoTech Receives New Patent on the Japanese Market

Scandinavian ChemoTech AB (publ) Receives Final Patent Approval in the EU for the Tumour Specific Control Unit in TSE™ Platform

High number of new and inexperienced directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Scandinavian ChemoTech AB (publ)'s TSE Technology Shows Great Initial Pre-Trial Results in India

Scandinavian Chemotech AB (Publ) Announces Demise of Göran Hellers, Co-Founder, Former Board Member

Scandinavian ChemoTech AB Receives Approval from the Us Patent Office

Third quarter 2021 earnings released

Scandinavian ChemoTech AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 18.000004 million.

Second quarter 2021 earnings released

Scandinavian ChemoTech Receives Approval from the European Patent Office

Scandinavian Chemotech AB Receives Approval for the CE Marking

First quarter 2021 earnings released

Full year 2020 earnings released: kr1.93 loss per share (vs kr3.79 loss in FY 2019)

CEO

Tenure

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd